CNS Autoantibody and Inflammatory Marker Investigation in Catatonia

Overview

About this study

The overall objective of this study is to compare seroprevalence rates, titers of central nervous system (CNS) autoantibodies, and inflammatory markers in catatonic patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Age 18-60, male or female, any race/ethnicity
Diagnosis of catatonia utilizing two screening tools, 1) the 23-item Bush-Francis Catatonia Rating Scale (BFCRS), and 2) the DSM-5 catatonic symptoms:3 out of 12 symptoms present [2, 33]

Exclusion Criteria:

Inability to speak English
Inability or lack of willingness to obtain informed consent from patient or legal authorized representative.
Involuntary treatment or hospitalization
Out patients with active suicidality as defined by a score of 2 or higher on question # 18 of the Inventory for Depressive Symptoms (IDS)
Active or unstable medical condition as evaluated by clinical interviewer
Presence of co-morbid Axis I or Axis II disorder that is the primary diagnosis and current focus of treatment

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Robert Morgan, M.D., Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Robert Morgan, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials